SG
$25.50
+0.57
(+2.31%)
As of Oct 5, 2026, 3:41 PM EDT
Price history
SpyGlass Pharma (SGP) is trading up at $25.50 (+2.31%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: February 6, 2026 · $16.00 offering · NASDAQ · View IPO details →
SpyGlass Pharma net income history (FY2024–FY2025)
Net income
| FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|
| Income statement | ||
| Operating income | −$27.1M | −$41.4M |
| Net income | −$29.2M | −$39.9M |
| EPS (diluted) | −$16.31 | −$17.98 |
| Balance sheet | ||
| Cash and equivalents | $16.3M | $96.4M |
| Total assets | $23.3M | $115.9M |
| Total liabilities | $11.2M | $10.2M |
| Shareholders' equity | −$60.5M | −$98.8M |
| Cash flow | ||
| Operating cash flow | −$22.0M | −$32.7M |
| Capital expenditure | $1.99M | $789.0K |
| Free cash flow | −$24.0M | −$33.5M |
| Share buybacks | $0 | $1.45M |
Net income
| Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Operating income | −$7.42M | −$9.30M | — | −$15.4M | −$22.0M |
| Net income | −$8.82M | −$8.68M | — | −$13.8M | −$19.9M |
| EPS (diluted) | −$3.96 | −$3.81 | — | −$0.69 | −$0.59 |
| Balance sheet | |||||
| Cash and equivalents | $58.0M | $127.2M | $96.4M | $238.9M | $223.1M |
| Total assets | — | — | $115.9M | $258.4M | $243.4M |
| Total liabilities | — | — | $10.2M | $8.27M | $11.1M |
| Shareholders' equity | −$68.9M | −$78.4M | −$98.8M | $250.1M | $232.4M |
| Cash flow | |||||
| Operating cash flow | −$8.20M | −$6.33M | — | −$13.5M | −$14.8M |
| Capital expenditure | $164.0K | $52.0K | — | $676.0K | $1.93M |
| Free cash flow | −$8.37M | −$6.38M | — | −$14.2M | −$16.8M |
From SpyGlass Pharma's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
About SpyGlass Pharma
- Headquarters
- Irvine, California From SEC filings, Oct 2026
Recent News (4)
-
Stifel reiterates SpyGlass Pharma stock Buy rating on acquisition
Stifel reiterates SpyGlass Pharma stock Buy rating on acquisition
-
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock o…
-
Kigen Automotive eSIM first to achieve GSMA eSA certification, bringing latest SGP.32 security to connected vehicle OEMs for long-life fleets With the industry's first eSA-certified eSIMs supporting the latest SGP.32 v1.3, Kigen delivers automotive-grade security, giving OEMs a common architecture for developing connected fleets – plus an i…
-
Kigen Automotive eSIM first to achieve GSMA eSA certification, bringing latest SGP.32 security to connected vehicle OEMs for long-life fleets With the industry's first eSA-certified eSIMs supporting the latest SGP.32 v1.3, Kigen delivers automotive-grade security, giving OEMs a common architecture for developing connected fleets – plus an i…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International